Long-Term Effectiveness of Quadruple Combination Therapy with Empagliflozin Versus Basal Long-Acting Insulin Therapy in Patients with Type 2 Diabetes: 3-Year Retrospective Observational Study
ConclusionEmpagliflozin was shown to perform as well as better than insulin when used as part of a quadruple drug regimen for regulating blood glucose levels in suboptimally controlled patients with T2D.Clinical Trial NumberNCT 05103306 (ClinicalTrials.gov).
Source: Diabetes Therapy - Category: Endocrinology Source Type: research
More News: Cardiology | Clinical Trials | Diabetes | Diabetes Type 2 | Empagliflozin | Endocrinology | Fortamet | Glimepiride | Heart | Insulin | Jardiance | Metformin | SGLT2 Inhibitors | Sodium | Study